SCHEMBL1840135

SCHEMBL1840135

Nc1nccc(-c2cc3c(-c4ccncc4)ccnc3[nH]2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 7/20 0.52
▸ CLK2 P49760 6/20 0.52
▸ CLK3 P49761 3/20 0.52
▸ GSK3B P49841 3/20 0.47
▸ PIM1 P11309 1/20 0.45
▸ HASPIN Q8TF76 1/20 0.45
▸ CDK9 P50750 7/20 0.45
▸ CCNA2 P20248 6/20 0.45
▸ CDK2 P24941 6/20 0.45
▸ CCNT1 O60563 5/20 0.45
▸ CDC7 O00311 5/20 0.44
▸ CCNA1 P78396 3/20 0.44
▸ PLK1 P53350 1/20 0.44
▸ NFATC1 O95644 1/20 0.44
▸ JAK2 O60674 2/20 0.43
▸ PDPK1 O15530 1/20 0.42
▸ CDK5 Q00535 1/20 0.42
▸ CDK5R1 Q15078 1/20 0.42
▸ IKBKB O14920 1/20 0.42
▸ CCNB2 O95067 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1838343 0.90 GSK3B (0.53) DYRK1ACLK2CLK3GSK3BCDK9
SCHEMBL1840513 0.88 GSK3B (0.46) DYRK1ACLK2CLK3GSK3BPIM1
SCHEMBL1839153 0.81 MAPK8 (0.49) DYRK1ACLK2CLK3GSK3BPIM1
SCHEMBL1841577 0.79 CHUK (0.45) DYRK1ACLK2CLK3GSK3BCDK9
SCHEMBL1842523 0.75 CCNT1 (0.56) GSK3BPIM1CDK9CCNA2CDK2
SCHEMBL2239570 0.75 CDK9 (0.54) DYRK1AGSK3BCDK9CCNA2CDK2
SCHEMBL1838419 0.72 CDC7 (0.47) DYRK1ACLK2CLK3CDC7CHUK
SCHEMBL2684649 0.71 HSP90AA1 (0.70) DYRK1AGSK3BPIM1HASPINCDK2
SCHEMBL1838178 0.70 CDC7 (0.51) DYRK1ACLK2GSK3BCDK9CCNT1
SCHEMBL18448555 0.70 CLK2 (0.81) DYRK1ACLK2CLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011526931-A — — 2011-10-20 — — JP claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 — — US claimed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 — — CN claimed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 — — EP claimed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 — — WO claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 — — US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 — — US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 — — US disclosed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 — — CN disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 DYRK1A 546/4885CLK2 582/4885CLK3 912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback